Background and objective: We investigated whether a high bolus dose of cisatracurium (8× ED95) given at induction can provide muscle relaxation for the major part of a cardiac procedure with hypothermic cardiopulmonary bypass, avoid important postoperative residual curarization and cause no waste of product. Methods: Twenty patients were randomly assigned either to Group 1 (n = 10) or Group 2 (n = 10). Those in Group 1 were given cisatracurium in a high bolus dose (0.4 mg kg−1). Those in Group 2 received cisatracurium 0.1mg kg−1 at induction followed after 30 min by a continuous infusion of cisatracurium. As an escape medication in case of patient movement, a bolus dose of cisatracurium 0.03 mg kg−1 was given. Results: In Group 1 (large cisatracurium bolus dose), the clinical duration of effect (until T1/T0 = 25%) was 110 min. Six of 10 patients in Group 1 required additional boluses of cisatracurium intraoperatively. Four of these six had received an additional bolus near the end of surgery and had a train‐of‐four (TOF) ratio = 0 at the end. The other four patients in Group 1 had a final TOF ratio >0.9. In Group 2 (continuous cisatracurium infusion), only two patients had a TOF ratio >0.9 at the end of surgery, no patient moved and none received additional boluses. The total amount of cisatracurium used in the bolus and infusion Groups was 34.5 ± 7.8 and 21.3 ± 5.7 mg, respectively (P = 0.0004). Conclusions: For continued neuromuscular block during hypothermic cardiac surgery, a high bolus dose of cisatracurium appears to be safe, although it is not an alternative to a continuous infusion, as its neuromuscular blockade does not cover the intraoperative period and a high incidence of movements occurs. In the patients who received a high bolus dose of cisatracurium, postoperative residual curarization appeared after additional boluses had been given. The consumption of cisatracurium by high bolus was significantly greater than with continuous infusion.
[1]
M. Struys,et al.
Postoperative residual curarization with cisatracurium and rocuronium infusions.
,
2002,
European journal of anaesthesiology.
[2]
J. Hendrickx,et al.
Dose requirements of infusions of cisatracurium or rocuronium during hypothermic cardiopulmonary bypass.
,
2000,
British journal of anaesthesia.
[3]
P. White,et al.
Reversal of neuromuscular blockade.
,
1998,
Anesthesia and analgesia.
[4]
D. Rosen,et al.
Elimination of drugs and toxins during cardiopulmonary bypass.
,
1997,
Journal of cardiothoracic and vascular anesthesia.
[5]
J. Wierda,et al.
Effects of hypothermic cardiopulmonary bypass on the pharmacodynamics and pharmacokinetics of rocuronium.
,
1995,
Journal of cardiothoracic and vascular anesthesia.
[6]
D. Reich,et al.
A Two-Center Comparison of the Cardiovascular Effects of Cisatracurium (Nimbex Trademmark) and Vecuronium in Patients with Coronary Artery Disease
,
1995,
Anesthesia and analgesia.
[7]
R. Welch,et al.
The in vitro degradation of cisatracurium, the R, cis‐R′‐isomer of atracurium, in human and rat plasma
,
1995,
Clinical pharmacology and therapeutics.
[8]
C. Lien,et al.
The Clinical Neuromuscular Pharmacology of 51W89 in Patients Receiving Nitrous Oxide/Opioid/Barbiturate Anesthesia
,
1995,
Anesthesiology.
[9]
E. Mortier,et al.
Cardiopulmonary Bypass and the Pharmacokinetics of Drugs
,
1989
.
[10]
B. Walton,et al.
Use of atracurium in cardiac surgery involving cardiopulmonary bypass with induced hypothermia.
,
1984,
British journal of anaesthesia.
[11]
E. Mortier,et al.
Cardiopulmonary bypass and the pharmacokinetics of drugs. An update.
,
1989,
Clinical pharmacokinetics.